Howard Kaufman MD

Dr. Howard L. Kaufman is the President and Chief Executive Officer at Ankyra Therapeutics. He is a leading authority on intratumoral immunotherapy. In his academic career he led pivotal studies of Talimogene laherparepvec in melanoma and avelumab in patients with Merkel cell carcinoma resulting in regulatory approvals. Dr. Kaufman was born in Chicago, Illinois and received his MD degree from Loyola University, completed a residency in General Surgery at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the National Cancer Institute. His academic positions included Division Chief of Surgical Oncology and Associate Director of the Cancer Center at Columbia University, Associate Dean and Cancer Center Director at Rush University, and he was a tenured professor at Rutgers University and and Associate Director of the Rutgers Cancer Institute of New Jersey. In 2016 he joined the biotechnology community and has served as Chief Medical Officer at Replimune, Head of Research and Development at Immuneering prior to leading Ankyra. He also maintains an academic appointment as a Senior Lecturer at Harvard Medical School and sees skin cancer patients at Massachusetts Eye & Ear Infirmary. Dr. Kaufman has published over 600 peer-reviewed scientific papers, books, review articles and abstracts. He is a member of numerous professional societies and served as President of the Society for Immunotherapy of Cancer. He received numerous awards including the Humanitarian Award from the Melanoma Research Foundation.